Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 84 weeks
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- The long-term extension of the SELECT-MONOTHERAPY trial assessed safety and efficacy of upadacitinib monotherapy in rheumatoid arthritis up to 84 weeks (study still ongoing).
- ACR50 response was achieved by 71% and 78% of patients continuing to receive upadacitinib 15 or 30 mg respectively.
- The safety profile associated with long-term upadacitinib monotherapy was consistent with an integrated analysis across the phase 3 program, and no new safety signals were identified through 84 weeks.
- Upadacitinib 15 or 30 mg monotherapy resulted in continued and sustained benefit through 84 weeks.
Presenting Author
Josef Smolen, MD
Medical University of Vienna
Vienna, Austria
Josef Smolen received his MD degree from the University of Vienna, Austria, and trained there in Immunology, Medicine and Rheumatology. He was a research fellow at the Arthritis Institute at NIH, Bethesda, MD, USA. From 1989 to 2017 he has been Chairman, 2nd Department of Medicine, Hietzing Hospital, Vienna; 1995-2018 he served as Professor of Medicine and Chairman, Division of Rheumatology, Medical University of Vienna, where he also acted as Chairman of the Department of Medicine 3 from 2007 to 2018. He is now Emeritus Professor of Medicine at the Medical University of Vienna, Austria. An author of several hundred original publications and lead investigator of many clinical trials, his major scientific interests concern elucidation of the pathogenesis of rheumatic diseases, translational research, outcomes and epidemiologic research, as well as novel therapies and therapeutic strategies in rheumatic diseases. Josef Smolen was President of EULAR from 2003 to 2005 and President of the Austrian Society of Rheumatology and Austrian Society of Immunology. He is a member of the Austrian Academy of Sciences, the German Academy of Sciences (Leopoldina), Fellow of the Royal College of Physicians (London) and Honorary Doctor of Lund University, Sweden, Leiden University, Netherlands, and Semmelweis University, Budapest. He is a co-editor of the textbook “Rheumatology” whose 8th edition is in preparation. He currently serves as editor-in-chief of Annals of the Rheumatic Diseases.
Presenter disclosures
J. Smolen, AbbVie, AstraZeneca, Eli Lilly, Celgene, Celltrion, Chugai, Gilead , ILTOO , Janssen, Kabi, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi
